Journal
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
Volume 5, Issue -, Pages 44-47Publisher
WOLTERS KLUWER MEDKNOW PUBLICATIONS
DOI: 10.4103/0973-1482.55141
Keywords
Malignant gliomas; neural protection; radiotherapy; radionecrosis; quality of life; 2-deoxy-D-glucose
Categories
Ask authors/readers for more resources
2-deoxy-D-glucose (2-DG), an inhibitor of glucose transport and glycolysis, enhances radiation damage selectively in tumor cells by modulating damage response pathways resulting in cell death in vitro and local tumor control. Phase I and II clinical trials in patients with malignant glioma have shown excellent tolerance to a combined treatment of orally administered 2-DG and hypofractionated radiotherapy without any acute toxicity and late radiation damage. Phase III efficacy trials are currently at an advanced stage. Re-exploratory surgery performed in 13 patients due to persistent symptoms of elevated ICP and mass effect at different follow-up periods revealed extensive tumor necrosis with well-preserved normal brain tissue adjoining the tumor included in the treatment volume as revealed by a histological examination. These observations are perhaps the first clinical evidences for differential effects of 2-DG on tumors and normal tissues in conformity with earlier in vitro and in vivo studies in normal and tumor-bearing mice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available